© 2020 MJH Life Sciences and OncLive. All rights reserved.
July 07, 2016
Jorge A. Garcia, MD, Department of Hematology and Oncology, discusses the results of the phase III METEOR trial, which compared the efficacy of cabozantinib (Cabometyx) versus everolimus (Afinitor) in patients with advanced renal cell carcinoma.
April 01, 2015
Jorge A. Garcia, MD, Department of Hematology and Oncology, Cleveland Clinic, discusses some of the challenges with immunotherapy in prostate cancer.